PRKCQ and neuroblastoma: In the current study, we have found that PRKCQ‐AS1 knockdown reduces MYCN nonamplified neuroblastoma cell proliferation, considerably inhibits clonogenic capacity, suppresses tumor progression and improves survival in two mouse models.